Lalezari, Jacob,
Development of PRO-140 (Leronlimab) as a treatment for COVID-19 [electronic resource] / Jacob Lalezari. - London : Henry Stewart Talks, 2020. - 1 online resource (1 streaming audio file (20 min.)). - Interviews on Covid-19, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Interviews on Covid-19. .
Audio interview. Title from title frames.
Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?
Access restricted to subscribers.
Mode of access: World Wide Web.
8159 Henry Stewart Talks
Coronavirus infections--Treatment.
COVID-19 (Disease)
Drug development.
CCR5 Receptor Antagonists--therapeutic use.
Coronavirus Infections--drug therapy.
COVID-19--drug therapy.
Drug Development.
Inflammation.
leronlimab.
Pharmaceutical Preparations.
Receptors, CCR5.
SARS-CoV-2.
Development of PRO-140 (Leronlimab) as a treatment for COVID-19 [electronic resource] / Jacob Lalezari. - London : Henry Stewart Talks, 2020. - 1 online resource (1 streaming audio file (20 min.)). - Interviews on Covid-19, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Interviews on Covid-19. .
Audio interview. Title from title frames.
Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?
Access restricted to subscribers.
Mode of access: World Wide Web.
8159 Henry Stewart Talks
Coronavirus infections--Treatment.
COVID-19 (Disease)
Drug development.
CCR5 Receptor Antagonists--therapeutic use.
Coronavirus Infections--drug therapy.
COVID-19--drug therapy.
Drug Development.
Inflammation.
leronlimab.
Pharmaceutical Preparations.
Receptors, CCR5.
SARS-CoV-2.